Local cytokine response upon respiratory syncytial virus infection

Immunology Letters

Volumn 136, Issue 2, 2011, Pages 122-129

  Bueno, Susan M ^a   González, Pablo A ^a   Riedel, Claudia A ^a,b   Carreño, Leandro J ^a   Vásquez, Abel E ^c   Kalergis, Alexis M ^a,d  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSIDAD ANDRÉS BELLO   (Chile)

^c INSTITUTO DE SALUD PÚBLICA DE CHILE   (Chile)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Cytokines; Immunopathology; Respiratory syncytial virus

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; EOTAXIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES;

AGE; ANTIGENIC VARIATION; ARTICLE; ASTHMA; CELLULAR IMMUNITY; CYTOKINE RELEASE; CYTOKINE RESPONSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; HOSPITALIZATION; HUMAN; IMMUNOMODULATION; LUNG INFILTRATE; LYMPHOCYTIC INFILTRATION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS VIRULENCE; WHEEZING;

EID: 79953026337     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2010.12.003     Document Type: Review

References (131)

1. Chavez-Bueno S., Mejias A., Jafri H.S., Ramilo O. Respiratory syncytial virus: old challenges and new approaches. Pediatr Ann 2005, 34:62-68.
2. Hacking D.J.H. Respiratory syncytial virus-viral biology and the host response. J Infect 2002, 45:18-24.
3. Harris J., Werling D. Binding and entry of respiratory syncytial virus into host cells and initiation of the innate immune response. Cell Microbiol 2003, 5:671-680.
4. Srikiatkhachorn A., Braciale T.J. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med 1997, 186:421-432.
5. Sigurs N., Aljassim F., Kjellman B., Robinson P.D., Sigurbergsson F., Bjarnason R., et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 2010, 65(12):1045-1052.
6. Beckham J.D., Cadena A., Lin J., Piedra P.A., Glezen W.P., Greenberg S.B., et al. Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J Infect 2005, 50:322-330.
7. Englund J.U., Piedra P.A., Jewell A., Patel K., Baxter B.B.E.W. Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults. Am Soc Microbiol 1996, 34:1649-1653.
8. Lanari M., Silvestri M., Rossi G.A. Respiratory syncytial virus risk factors in late preterm infants. J Matern Fetal Neonatal Med 2009, 2(Suppl. 3):102-107.
9. Harker J., Bukreyev A., Collins P.L., Wang B., Openshaw P.J.M.J.S.T. Virally delivered cytokines alter the immune response to future lung infections. J Virol 2007, JVI.01544-01507.
10. Stein R.T. Long-term airway morbidity following viral LRTI in early infancy: recurrent wheezing or asthma?. Paediatr Respir Rev 2009, 10(Suppl. 1):29-31.
11. Eisenhut M., Thorburn K. Hepatitis associated with severe respiratory syncytial virus-positive lower respiratory tract infection. Scand J Infect Dis 2002, 34:235.
12. Sweetman L.L., Ng Y.T., Butler I.J., Bodensteiner J.B. Neurologic complications associated with respiratory syncytial virus. Pediatr Neurol 2005, 32:307-310.
13. Eisenhut M., Sidaras D., Johnson R., Newland P., Thorburn K. Cardiac troponin T levels and myocardial involvement in children with severe respiratory syncytial virus lung disease. Acta Paediatr 2004, 93:887-890.
14. van Steensel-Moll H.A., Hazelzet J.A., van der Voort E., Neijens H.J., Hackeng W.H. Excessive secretion of antidiuretic hormone in infections with respiratory syncytial virus. Arch Dis Child 1990, 65:1237-1239.
15. Eisenhut M. Extrapulmonary manifestations of severe RSV bronchiolitis. Lancet 2006, 368:988.
16. Stock C., Teyssier G., Pichot V., Goffaux P., Barthelemy J.C., Patural H. Autonomic dysfunction with early respiratory syncytial virus-related infection. Auton Neurosci. 2010, 156(1-2):90-95.
17. Nadal D., Wunderli W., Meurmann O., Briner J., Hirsig J. Isolation of respiratory syncytial virus from liver tissue and extrahepatic biliary atresia material. Scand J Infect Dis 1990, 22:91-93.
18. Otake Y., Yamagata T., Morimoto Y., Imi M., Mori M., Aihara T., et al. Elevated CSF IL-6 in a patient with respiratory syncytial virus encephalopathy. Brain Dev 2007, 29:117-120.
19. Ventre K., Randolph A.G. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 2007, CD000181.
20. Everard M.L., Swarbrick A., Rigby A.S., Milner A.D. The effect of ribavirin to treat previously healthy infants admitted with acute bronchiolitis on acute and chronic respiratory morbidity. Respir Med 2001, 95:275-280.
21. Randolph A.G., Wang E.E. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract. Cochrane Database Syst Rev 2000, CD000181.
22. Liu P., Jamaluddin M., Li K., Garofalo R., Casola A., Brasier A. Retinoic acid-inducible gene I mediates early antiviral response and toll-like receptor 3 expression in respiratory syncytial virus-infected airway epithelial cells. J Virol 2007, 81:1401-1411.
23. Xie X.H., Law H.K., Wang L.J., Li X., Yang X.Q., Liu E.M. Lipopolysaccharide induces IL-6 production in respiratory syncytial virus-infected airway epithelial cells through the toll-like receptor 4 signaling pathway. Pediatr Res 2009, 65:156-162.
24. Groskreutz D.J., Monick M.M., Powers L.S., Yarovinsky T.O., Look D.C.G.W.H. Respiratory syncytial virus induces TLR3 protein and protein kinase R, leading to increased double-stranded RNA responsiveness in airway epithelial cells. J Immunol 2006, 176:1733-1740.
25. Rudd B.D., Burstein E., Duckett C.S., Li X., Lukacs N.W. Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression. J Virol 2005, 79:3350-3357.
26. Jewell N.A., Vaghefi N., Mertz S.E., Akter P., Peebles R.S., Bakaletz L.O., et al. Differential type I interferon induction by respiratory syncytial virus and influenza A virus in vivo. J Virol 2007, 81:9790-9800.
27. Pichlmair A., Schulz O., Tan C.P., Naslund T.I., Liljestrom P., Weber F., et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 2006, 314:997-1001.
28. Murawski M.R., Bowen G.N., Cerny A.M., Anderson L.J., Haynes L.M., Tripp R.A., et al. Respiratory syncytial virus activates innate immunity through toll-like receptor 2. J Virol 2009, 83:1492-1500.
29. Scagnolari C., Midulla F., Pierangeli A., Moretti C., Bonci E., Berardi R., et al. Gene expression of nucleic acid-sensing pattern recognition receptors in children hospitalized for respiratory syncytial virus-associated acute bronchiolitis. Clin Vaccine Immunol 2009, 16:816-823.
30. Monick M.M., Yarovinsky T.O., Powers L.S., Butler N.S., Carter A.B., Gudmundsson G., et al. Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. J Biol Chem 2003, 278:53035-53044.
31. Halfhide C.P., Brearey S.P., Flanagan B.F., Hunt J.A., Howarth D., Cummerson J., et al. Neutrophil TLR4 expression is reduced in the airways of infants with severe bronchiolitis. Thorax 2009, 64:798-805.
32. Wheeler D.S., Chase M.A., Senft A.P., Poynter S.E., Wong H.R., Page K. Extracellular Hsp72, an endogenous DAMP, is released by virally infected airway epithelial cells and activates neutrophils via Toll-like receptor (TLR)-4. Respir Res 2009, 10:31.
33. Shingai M., Azuma M., Ebihara T., Sasai M., Funami K., Ayata M., et al. Soluble G protein of respiratory syncytial virus inhibits Toll-like receptor 3/4-mediated IFN-beta induction. Int Immunol 2008, 20:1169-1180.
34. Rudd B.D., Schaller M.A., Smit J.J., Kunkel S.L., Neupane R., Kelley L., et al. MyD88-mediated instructive signals in dendritic cells regulate pulmonary immune responses during respiratory virus infection. J Immunol 2007, 178:5820-5827.
35. Oshansky C.M., Krunkosky T.M., Barber J., Jones L.P., Tripp R.A. Respiratory syncytial virus proteins modulate suppressors of cytokine signaling 1 and 3 and the type I interferon response to infection by a toll-like receptor pathway. Viral Immunol 2009, 22:147-161.
36. Kurt-Jones E.A., Popova L., Kwinn L., Haynes L.M., Jones L.P., Tripp R.A., et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000, 1:398-401.
37. Perez-Yarza E.G., Moreno A., Lazaro P., Mejias A., Ramilo O. The association between respiratory syncytial virus infection and the development of childhood asthma: a systematic review of the literature. Pediatr Infect Dis J 2007, 26:733-739.
38. Stark J.M., Stark M.A., Colasurdo G.N., LeVine A.M. Decreased bacterial clearance from the lungs of mice following primary respiratory syncytial virus infection. J Med Virol 2006, 78:829-838.
39. Huang S., Wei W., Yun Y. Upregulation of TLR7 and TLR3 gene expression in the lung of respiratory syncytial virus infected mice. Wei Sheng Wu Xue Bao 2009, 49:239-245.
40. Schlender J., Hornung V., Finke S., Gunthner-Biller M., Marozin S., Brzozka K., et al. Inhibition of toll-like receptor 7- and 9-mediated alpha/beta interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virus. J Virol 2005, 79:5507-5515.
41. Lukacs N.W., Smit J.J., Mukherjee S., Morris S.B., Nunez G., Lindell D.M. Respiratory virus-induced TLR7 activation controls IL-17-associated increased mucus via IL-23 regulation. J Immunol 2010, 185:2231-2239.
42. Johnson T.R., Rao S., Seder R.A., Chen M., Graham B.S. TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity. Vaccine 2009, 27:3045-3052.
43. Spann K.M., Tran K.C., Chi B., Rabin R.L.P.L.C. Suppression of the induction of alpha, beta, and gamma interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages. J Virol 2004, 78:4363-4369.
44. Senft A.P., Taylor R.H., Lei W., Campbell S.A., Tipper J.L., Martinez M.J., et al. Respiratory syncytial virus impairs macrophage IFN-alpha/beta- and IFN-gamma-stimulated transcription by distinct mechanisms. Am J Respir Cell Mol Biol 2010, 42:404-414.
45. Bueno S.M., Gonzalez P.A., Pacheco R., Leiva E.D., Cautivo K.M., Tobar H.E., et al. Host immunity during RSV pathogenesis. Int Immunopharmacol 2008, 8:1320-1329.
46. Haeberle H.A., Takizawa R., Casola A., Brasier A.R., Dieterich H.J., Van Rooijen N., et al. Respiratory syncytial virus-induced activation of nuclear factor-κB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways. J Infect Dis 2002, 186:1199-1206.
47. Yoboua F., Martel A., Duval A., Mukawera E., Grandvaux N. Respiratory syncytial virus-mediated NF-{kappa}B p65 phosphorylation at serine 536 is dependent on RIG-I, TRAF6, and IKK{beta}. J Virol 2010, 84:7267-7277.
48. Lee D.C., Harker J.A., Tregoning J.S., Atabani S.F., Johansson C., Schwarze J., et al. CD25+ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection. J Virol 2010, 84:8790-8798.
49. Cautivo K.M., Bueno S.M., Cortes C.M., Wozniak A., Riedel C.A., Kalergis A.M. Efficient lung recruitment of respiratory syncytial virus specific Th1 cells induced by recombinant bacillus Calmette-Guerin promotes virus clearance and protects from infection. J Immunol 2010, 185:7633-7645.
50. Janssen R., Bont L., Siezen C.L., Hodemaekers H.M., Ermers M.J., Doornbos G., et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes. J Infect Dis 2007, 196:826-834.
51. Choudhary S., Boldogh S., Garofalo R., Jamaluddin M., Brasier A.R. Respiratory syncytial virus influences NF-kappaB-dependent gene expression through a novel pathway involving MAP3K14/NIK expression and nuclear complex formation with NF-kappaB2. J Virol 2005, 79:8948-8959.
52. Hosakote Y.M., Liu T., Castro S.M., Garofalo R.P., Casola A. Respiratory syncytial virus induces oxidative stress by modulating antioxidant enzymes. Am J Respir Cell Mol Biol 2009, 41:348-357.
53. Jamaluddin M., Tian B., Boldogh I., Garofalo R.P., Brasier A.R. Respiratory syncytial virus infection induces a reactive oxygen species-MSK1-phospho-Ser-276 RelA pathway required for cytokine expression. J Virol 2009, 83:10605-10615.
54. Spann K.M., Tran K.C., Collins P.L. Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. J Virol 2005, 79:5353-5362.
55. Reimers K., Buchholz K., Werchau H. Respiratory syncytial virus M2-1 protein induces the activation of nuclear factor kappa B. Virology 2005, 331:260-268.
56. Becker Y. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy-a review. Virus Genes 2006, 33:235-252.
57. Culley F.J., Pennycook A.M., Tregoning J.S., Dodd J.S., Walzl G., Wells T.N., et al. Role of CCL5 (RANTES) in viral lung disease. J Virol 2006, 80:8151-8157.
58. Tripp R.A., Oshansky C., Alvarez R. Cytokines and respiratory syncytial virus infection. Proc Am Thorac Soc 2005, 2:147-149.
59. Oshansky C.M., Barber J.P., Crabtree J., Tripp R.A. Respiratory syncytial virus F and G proteins induce interleukin 1alpha, CC, and CXC chemokine responses by normal human bronchoepithelial cells. J Infect Dis 2010, 201:1201-1207.
60. Culley F.J., Pennycook A.M.J.J.S., Hussell T.T.P.J.M.O. Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology. J Virol 2006, 80:4521-4527.
61. Garofalo R.P., Patti J., Hintz K.A., Hill V., Ogra P.L., Welliver R.C. Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J Infect Dis 2001, 184:393-399.
62. Cannon M.J., Openshaw P.J.B.A.A. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med 1988, 168:1163-1168.
63. Lukens M.V., van de Pol A.C., Coenjaerts F.E., Jansen N.J., Kamp V.M., Kimpen J.L., et al. A systemic neutrophil response precedes robust CD8(+) T-cell activation during natural respiratory syncytial virus infection in infants. J Virol 2010, 84:2374-2383.
64. Bennett B.L., Garofalo R.P., Cron S.G., Hosakote Y.M., Atmar R.L., Macias C.G., et al. Immunopathogenesis of respiratory syncytial virus bronchiolitis. J Infect Dis 2007, 195:1532-1540.
65. Bermejo-Martin J.F., Garcia-Arevalo M.C., De Lejarazu R.O., Ardura J., Eiros J.M., Alonso A., et al. Predominance of Th2 cytokines, CXC chemokines and innate immunity mediators at the mucosal level during severe respiratory syncytial virus infection in children. Eur Cytokine Netw 2007, 18:162-167.
66. Bartz H., Buning-Pfaue F., Turkel O.U.S. Respiratory syncytial virus induces prostaglandin E2, IL-10 and IL-11 generation in antigen presenting cells. Clin Exp Immunol 2002, 129:438-445.
67. van Benten I.J., van Drunen C.M., Koevoet J.L., Koopman L.P., Hop W.C., Osterhaus A.D., et al. Reduced nasal IL-10 and enhanced TNFalpha responses during rhinovirus and RSV-induced upper respiratory tract infection in atopic and non-atopic infants. J Med Virol 2005, 75:348-357.
68. Grissell T.V., Powell H., Shafren D.R., Boyle M.J., Hensley M.J., Jones P.D., et al. Interleukin-10 gene expression in acute virus-induced asthma. Am J Respir Crit Care Med 2005, 172:433-439.
69. Stevens W.W., Sun J., Castillo J.P., Braciale T.J. Pulmonary eosinophilia is attenuated by early responding CD8(+) memory T cells in a murine model of RSV vaccine-enhanced disease. Viral Immunol 2009, 22:243-251.
70. Jartti T., Paul-Anttila M., Lehtinen P., Parikka V., Vuorinen T., Simell O., et al. Systemic T-helper and T-regulatory cell type cytokine responses in rhinovirus vs. respiratory syncytial virus induced early wheezing: an observational study. Respir Res 2009, 10:85.
71. Vieira R.A., Diniz E.M., Ceccon M.E. Correlation between inflammatory mediators in the nasopharyngeal secretion and in the serum of children with lower respiratory tract infection caused by respiratory syncytial virus and disease severity. J Bras Pneumol 2010, 36:59-66.
72. Hsu C.Y., Liu H.E., Sheu F.Y., Leu S.J., Chiang B.L., Hsiao G., et al. Synergistic therapeutic effects of combined adenovirus-mediated interleukin-10 and interleukin-12 gene therapy on airway inflammation in asthmatic mice. J Gene Med 2010, 12:11-21.
73. Connors M., Giese N.A., Kulkarni A.B., Firestone C.Y., Morse H.C.R.M.B. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 1994, 68:5321-5325.
74. Gonzalez P.A., Prado C.E., Leiva E.D., Carreño L.J., Bueno S.M., Riedel C.A., et al. Respiratory syncytial virus impairs T cell activationby preventing synapse assembly with dendritic cells. Proc Natl Acad Sci USA 2008, 105:1499-5004.
75. Gonzalez P.A., Bueno S.M., Riedel C.A., Kalergis A.M. Impairment of T cell immunity by the respiratory syncytial virus: targeting virulent mechanisms for therapy and profilaxis. Curr Med Chem 2009, 16:4609-4625.
76. Urry Z., Xystrakis E., Hawrylowicz C.M. Interleukin-10-secreting regulatory T cells in allergy and asthma. Curr Allergy Asthma Rep 2006, 6:363-371.
77. Ruan Y., Okamoto Y., Matsuzaki Z., Endo S., Matsuoka T., Kohno T., et al. Suppressive effect of locally produced interleukin-10 on respiratory syncytial virus infection. Immunology 2001, 104:355-360.
78. Hansdottir S., Monick M.M., Lovan N., Powers L., Gerke A., Hunninghake G.W. Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-linked chemokines and cytokines in airway epithelium while maintaining the antiviral state. J Immunol 2010, 184:965-974.
79. Uhl E.W., Clarke T.J., Hogan R.J. Differential expression of nuclear factor-kappaB mediates increased pulmonary expression of tumor necrosis factor-alpha and virus-induced asthma. Viral Immunol 2009, 22:79-89.
80. Puthothu B., Bierbaum S., Kopp M.V., Forster J., Heinze J., Weckmann M., et al. Association of TNF-alpha with severe respiratory syncytial virus infection and bronchial asthma. Pediatr Allergy Immunol 2009, 20:157-163.
81. Amanatidou V., Sourvinos G., Apostolakis S., Neonaki P., Tsilimigaki A., Krambovitis E., et al. RANTES promoter gene polymorphisms and susceptibility to severe respiratory syncytial virus-induced bronchiolitis. Pediatr Infect Dis J 2008, 27:38-42.
82. García-Sastre A.C.A.B. Type 1 interferons and the virus-host relationship: a lesson in Détente. Science 2006, 312:879-882.
83. Claudinon J., Gonnord P., Beslard E., Marchetti M., Mitchell K., Boularan C., et al. Palmitoylation of interferon-alpha (IFN-alpha) receptor subunit IFNAR1 is required for the activation of Stat1 and Stat2 by IFN-alpha. J Biol Chem 2009, 284:24328-24340.
84. Li Z., Strunk J.J., Lamken P., Piehler J., Walz T. The EM structure of a type I interferon-receptor complex reveals a novel mechanism for cytokine signaling. J Mol Biol 2008, 377:715-724.
85. Martinez I., Lombardia L., Garcia-Barreno B., Dominguez O., Melero J.A. Distinct gene subsets are induced at different time points after human respiratory syncytial virus infection of A549 cells. J Gen Virol 2007, 88:570-581.
86. Boo K.H., Yang J.S. Intrinsic cellular defenses against virus infection by antiviral type I interferon. Yonsei Med J 2010, 51:9-17.
87. Horvath C.M., Stark G.R., Kerr I.M., Darnell J.E.J. Interactions between STAT and non-STAT proteins in the interferon-stimulated gene factor 3 transcription complex. Mol Cell Biol 1996, 16:6957-6964.
88. Asselin-Paturel C.G.T. Production of type I interferons: plasmacytoid dendritic cells and beyond. JEM 2005, 202:461-465.
89. Duhen T., Herschke F., Azocar O., Druelle J., Plumet S., Delprat C., et al. Cellular receptors, differentiation and endocytosis requirements are key factors for type I IFN response by human epithelial, conventional and plasmacytoid dendritic infected cells by measles virus. Virus Res 2010, 152(1-2):115-125.
90. Lo M.S., Brazas R.M., Holtzman M.J. Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of stat2 expression and alpha/beta interferon responsiveness. J Virol 2005, 79:9315-9319.
91. Swedan S., Musiyenko A., Barik S. Respiratory syncytial virus nonstructural proteins decrease levels of multiple members of the cellular interferon pathways. J Virol 2009, 83:9682-9693.
92. Elliott J., Lynch O.T., Qian Y.S., Boyd P., Burrows C.R., Buick J.F., et al. Respiratory syncytial virus NS1 protein degrades STAT2 by using the elongin-cullin E3 ligase. J Virol 2007, 81:3428-3436.
93. Durbin J.E., Johnson T.R., Durbin R.K., Mertz S.E., Morotti R.A., Peebles R.S.B.S.G. The role of IFN in respiratory syncytial virus pathogenesis. J Immunol 2002, 168:2944-2952.
94. Johnson T.R., Mertz S.E., Gitiban N., Hammond S., LeGallo R., Durbin R.K.J.E.D. Role for innate IFNs in determining respiratory syncytial virus immunopathology. J Immunol 2005, 174:7234-7241.
95. Cordey S., Junier T., Gerlach D., Gobbini F., Farinelli L., Zdobnov E.M., et al. Rhinovirus genome evolution during experimental human infection. PLoS ONE 2010, 5:e10588.
96. Nelson M., Spiro D., Wentworth D., Beck E., Fan J., Ghedin E., et al. The early diversification of influenza A/H1N1pdm. PLoS Curr Influenza 2009, RRN1126.
97. Peret T.C., Hall C.B., Hammond G.W., Piedra P.A., Storch G.A., Sullender W.M., et al. Circulation patterns of group A and B human respiratory syncytial virus genotypes in 5 communities in North America. J Infect Dis 2000, 181:1891-1896.
98. Mufson M.A., Orvell C., Rafnar B., Norrby E. Two distinct subtypes of human respiratory syncytial virus. J Gen Virol 1985, 66(Pt 10):2111-2124.
99. Anderson L.J., Hierholzer J.C., Tsou C., Hendry R.M., Fernie B.F., Stone Y., et al. Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis 1985, 151:626-633.
100. Johnson P.R., Spriggs M.K., Olmsted R.A., Collins P.L. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci USA 1987, 84:5625-5629.
101. Sullender W.M., Mufson M.A., Anderson L.J., Wertz G.W. Genetic diversity of the attachment protein of subgroup B respiratory syncytial viruses. J Virol 1991, 65:5425-5434.
102. Galiano M.C., Luchsinger V., Videla C.M., De Souza L., Puch S.S., Palomo C., et al. Intragroup antigenic diversity of human respiratory syncytial virus (group A) isolated in Argentina and Chile. J Med Virol 2005, 77:311-316.
103. Sullender W.M. Respiratory syncytial virus genetic and antigenic diversity. Clin Microbiol Rev 2000 Jan, 13(1):1-15. [table of contents].
104. Struck A., Forster J., Ihorst G., Werchau H., Konig W., Konig B. Respiratory syncytial virus: G gene genotype and disease severity. Pediatr Infect Dis J 2004, 23:1000-1002.
105. Connor A.L., Bevitt D.J., Toms G.L. Comparison of human respiratory syncytial virus A2 and 8/60 fusion glycoprotein gene sequences and mapping of sub-group specific antibody epitopes. J Med Virol 2001, 63:168-177.
106. Plows D.J., Pringle C.R. Variation in the fusion glycoprotein gene of human respiratory syncytial virus subgroup A. Virus Genes 1995, 11:37-45.
107. Pollack P., Groothuis J.R. Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV. J Infect Chemother 2002, 8:201-206.
108. Lukacs N.W., Moore M.L., Rudd B.D., Berlin A.A., Collins R.D., Olson S.J., et al. Differential immune responses and pulmonary pathophysiology are induced by two different strains of respiratory syncytial virus. Am J Pathol 2006, 169:977-986.
109. Bueno S.M., Gonzalez P.A., Cautivo K.M., Mora J.E., Leiva E.D., Tobar H.E., et al. Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. Proc Natl Acad Sci USA 2008, 105:20822-20827.
110. Chavez-Bueno S., Mejias A., Gomez A.M., Olsen K.D., Rios A.M., Fonseca-Aten M., et al. Respiratory syncytial virus-induced acute and chronic airway disease is independent of genetic background: an experimental murine model. Virol J 2005, 2:46.
111. Tian M., Liu F., Wen G.Y., Shi S.Y., Chen R.H., Zhao D.Y. Effect of variation in RANTES promoter on serum RANTES levels and risk of recurrent wheezing after RSV bronchiolitis in children from Han, Southern China. Eur J Pediatr 2009, 168:963-967.
112. Tulic M.K., Hurrelbrink R.J., Prele C.M., Laing I.A., Upham J.W., Le Souef P.P.D.S.P.G.H. TLR4 polymorphisms mediate impaired responses to respiratory syncytial virus and lipopolysaccharide. J Immunol 2007, 179:132-140.
113. Douville R.N., Lissitsyn Y., Hirschfeld A.F., Becker A.B., Kozyrskyj A.L., Liem J., et al. TLR4 Asp299Gly and Thr399Ile polymorphisms: no impact on human immune responsiveness to LPS or respiratory syncytial virus. PLoS ONE 2010, 5:e12087.
114. Forton J.T., Rowlands K., Rockett K., Hanchard N., Herbert M., Kwiatkowski D.P., et al. Genetic association study for RSV bronchiolitis in infancy at the 5q31 cytokine cluster. Thorax 2009, 64:345-352.
115. Schuurhof A., Bont L., Siezen C.L., Hodemaekers H., van Houwelingen H.C., Kimman T.G., et al. Interleukin-9 polymorphism in infants with respiratory syncytial virus infection: an opposite effect in boys and girls. Pediatr Pulmonol 2010, 45:608-613.
116. Tregoning J.S., Yamaguchi Y., Wang B., Mihm D., Harker J.A., Bushell E.S., et al. Genetic susceptibility to the delayed sequelae of neonatal respiratory syncytial virus infection is MHC dependent. J Immunol 2010, 185:5384-5391.
117. Leung A.K., Kellner J.D., Davies H.D. Respiratory syncytial virus bronchiolitis. J Natl Med Assoc 2005, 97:1708-1713.
118. Culley F.J., Pollott J., Openshaw P.J.M. Age at first viral infection determines the pattern of t cell-mediated disease during reinfection in adulthood. JEM 2002, 196:1381-1386.
119. Ballard P.L., Merrill J.D., Godinez R.I., Godinez M.H., Truog W.E., Ballard R.A. Surfactant protein profile of pulmonary surfactant in premature infants. Am J Respir Crit Care Med 2003, 168:1123-1128.
120. Kajekar R. Environmental factors and developmental outcomes in the lung. Pharmacol Ther 2007, 114:129-145.
121. Prescott S.L. The development of respiratory inflammation in children. Paediatr Respir Rev 2006, 7:89-96.
122. Wainwright C. Acute viral bronchiolitis in children - a very common condition with few therapeutic options. Paediatr Respir Rev 2010 Mar, 11(1):39-45. quiz 45. Epub 2009 Nov 26.
123. Unger S., Cunningham S. Effect of oxygen supplementation on length of stay for infants hospitalized with acute viral bronchiolitis. Pediatrics 2008, 121:470-475.
124. Kneyber M.C., van Heerde M., Twisk J.W., Plotz F.B., Markhors D.G. Heliox reduces respiratory system resistance in respiratory syncytial virus induced respiratory failure. Crit Care 2009, 13:R71.
125. Murai H., Terada A., Mizuno M., Asai M., Hirabayashi Y., Shimizu S., et al. IL-10 and RANTES are elevated in nasopharyngeal secretions of children with respiratory syncytial virus infection. Allergol Int 2007, 56:157-163.
126. Dodd J.S., Lum E., Goulding J., Muir R., Van Snick J., Openshaw P.J. IL-9 regulates pathology during primary and memory responses to respiratory syncytial virus infection. J Immunol 2009, 183:7006-7013.
127. Tekkanat K.K., Maassab H., Miller A., Berlin A.A., Kunkel S.L., Lukacs N.W. RANTES (CCL5) production during primary respiratory syncytial virus infection exacerbates airway disease. Eur J Immunol 2002, 32:3276-3284.
128. Elliott M.B., Tebbey P.W., Pryharski K.S., Scheuer C.A., Laughlin T.S., Hancock G.E. Inhibition of respiratory syncytial virus infection with the CC chemokine RANTES (CCL5). J Med Virol 2004, 73:300-308.
129. Kallal L.E., Schaller M.A., Lindell D.M., Lira S.A., Lukacs N.W. CCL20/CCR6 blockade enhances immunity to RSV by impairing recruitment of DC. Eur J Immunol 2010, 40:1042-1052.
130. Matthews S.P., Tregoning J.S., Coyle A.J., Hussell T., Openshaw P.J. Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection. J Virol 2005, 79:2050-2057.
131. Haeberle H.A., Kuziel W.A., Dieterich H.J., Casola A., Gatalica Z., Garofalo R.P. Inducible expression of inflammatory chemokines in respiratory syncytial virus-infected mice: role of MIP-1alpha in lung pathology. J Virol 2001, 75:878-890.